JPMorgan analyst Anne Samuel raised the firm’s price target on Health Catalyst to $13 from $10 and keeps an Overweight rating on the shares. The analyst updated the company’s model post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst to Participate in Upcoming Investor Conferences
- Health Catalyst price target lowered to $11 from $14 at Piper Sandler
- Health Catalyst price target lowered to $7 from $8 at Stephens
- Health Catalyst expands partnership with Contexture
- Health Catalyst expands partnership with South Dakota Health Link